Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT06544655
Official study title

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Study summary

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986484 and Nivolumab

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 17, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?9 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: BMS-986484; Biological: Nivolumab; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Fluorouracil; Drug: Calcium folinate
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
  • Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
  • Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Reasons someone may not be able to joinExclusion criteria
  • History of or with active interstitial lung disease or pulmonary fibrosis.
  • Active, known, or suspected autoimmune disease.
  • Serious uncontrolled medical disorders.
  • New onset, non-catheter-associated venous thromboembolism within the past 6 months.
  • Other protocol-defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Local Institution - 0003Tucson, Arizona
  • Local Institution - 0007Los Angeles, California
  • Local Institution - 0011Grand Rapids, Michigan
  • Local Institution - 0004Sioux Falls, South Dakota
  • Local Institution - 0013San Antonio, Texas
  • Local Institution - 0021Darlinghurst, New South Wales
  • Local Institution - 0019Elizabeth Vale, South Australia
  • Local Institution - 0017Toronto, Ontario
  • Local Institution - 0016Montreal, Quebec

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 17, 2026. Always confirm current availability with the study team.

View original record ↗